|
|
|
|
|
mil. € |
|
2021 |
2022 |
2023 |
2024 |
2025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trh |
|
1250,000 |
1300,000 |
1320,000 |
1350,000 |
1360,000 |
|
|
|
|
Adjusted na patent drugs |
70% |
875,000 |
910,000 |
924,000 |
945,000 |
952,000 |
|
|
|
|
|
|
839,300 |
802,180 |
764,480 |
725,920 |
687,080 |
|
|
|
|
|
|
|
18,465 |
17,648 |
16,819 |
15,970 |
|
|
|
|
Nárast patented drugs |
|
|
18,460 |
36,110 |
52,930 |
68,900 |
|
|
|
|
Generická obmena prepočítaná na rok* |
10% |
-87,500 |
-91,000 |
-92,400 |
-94,500 |
-95,200 |
|
|
|
|
Adjusted na next generation drugs /inovácie# |
80% |
-70,000 |
-72,800 |
-73,920 |
-75,600 |
-76,160 |
|
|
|
|
Generiká |
60% |
-42,000 |
-43,680 |
-44,352 |
-45,360 |
-45,696 |
|
|
|
|
Biosimilars |
40% |
-28,000 |
-29,120 |
-29,568 |
-30,240 |
-30,464 |
|
|
|
|
Úspora na verejných zdrojoch generiká |
55% |
-23,100 |
-24,020 |
-24,390 |
-24,950 |
-25,130 |
|
|
|
|
Úspora na verejných zdrojoch biosimilars |
45% |
-12,600 |
-13,100 |
-13,310 |
-13,610 |
-13,710 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Spolu úspora |
|
-35,700 |
-37,120 |
-37,700 |
-38,560 |
-38,840 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
vs rok 2021 generické lieky |
|
|
-24,020 |
-48,410 |
-73,360 |
-98,490 |
|
|
|
|
vs rok 2021 biosimilárne lieky |
|
|
-13,100 |
-26,410 |
-40,020 |
-53,730 |
|
|
|
|
Spolu generiká a biosimilárne lieky |
|
|
-37,120 |
-74,820 |
-113,380 |
-152,220 |
|
|
|
|
* dĺžka patentu 10 rokov |
|
|
|
|
|
|
|
|
|
|
#predpoklad, že 20% pacientov prejde na drahšie inovácie |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|